NovoCure Ltd — Director's Dealing 2022

Nov 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-11-01

Reporting Person: Leonard Frank X (President, CNS Cancers US)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-01	Ordinary Shares	A	6830	—	Acquired	50456	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-01	Options to Buy Ordinary Shares	$73.2	A	11609	Acquired	2032-10-31	Ordinary Shares (11609.0)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest in equal installments on each of November 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F2: Options to buy 11,609 ordinary shares will vest and become exercisable in equal installments on each of November 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.